[Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment]

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):481-6.
[Article in Chinese]
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Aspirin / administration & dosage
  • Aspirin / therapeutic use
  • Bevacizumab
  • Hemorrhage / chemically induced
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / drug therapy
  • Intestinal Perforation / chemically induced*
  • Intestinal Perforation / surgery
  • Neoplasms / drug therapy
  • Proteinuria / chemically induced*
  • Thromboembolism / chemically induced*
  • Thromboembolism / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Angiotensin-Converting Enzyme Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Aspirin